[2,4-bis(hydroxycarbonyl)butyl][3-amino-3-(hydroxycarbonyl)propyl]phosphinic acid | 763917-89-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [2,4-bis(hydroxycarbonyl)butyl][3-amino-3-(hydroxycarbonyl)propyl]phosphinic acid
• 英文别名: 2-[(3-amino-3-carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid；2-[[(3-amino-3-carboxypropyl)-hydroxyphosphoryl]methyl]pentanedioic acid
• CAS: 763917-89-1
• 化学式: C₁₀H₁₈NO₈P
• 分子量: 311.229
• InChiKey: YLHAQDFYEKJARV-UHFFFAOYSA-N

物化性质

• 熔点：
  181-187 °C (decomp)(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  720.6±60.0 °C(Predicted)
• 密度：
  1.528±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -5
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  175
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  [185Re-MAS3]-NHS 、 [2,4-bis(hydroxycarbonyl)butyl][3-amino-3-(hydroxycarbonyl)propyl]phosphinic acid 在 三乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  WO2008/27995

  摘要：

  公开号：
• 作为产物：
  描述：

  在 盐酸 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 [2,4-bis(hydroxycarbonyl)butyl][3-amino-3-(hydroxycarbonyl)propyl]phosphinic acid
  参考文献：
  名称：

  Synthesis of phosphinic acids on the basis of hypophosphites: VI. General methods for synthesis of pseudo-γ-glutamylpeptides

  摘要：

  A general method for synthesis of 2-substituted pseudo-gamma-glutamylpeptides, namely, [2-(hydroxy-carbonyl)ethyl][3-amino-3-(hydroxycarbonyl)propyl]phosphinic acids I which are phosphinic acid analogs of,gamma-glutamylpeptides. Bis(trimethylsilyl) hypophosphite (IV) formed from ammonium hypophosphite (II) in situ was added to the respective ck-substituted acrylate to form bis(trimethylsilyl) [2-R-2-(alkoxycarbonyl)ethyl]phosphonites V. Treatment of compounds V in situ with excess dibromoethane followed by alcoholysis gave [2-R-2-( alkoxycarbon),I)ethyl](2-bromoethyl)phosphonic acids VI which without isolation were treated with excess triethyl orthoformate. The sirnultanious esterification and dehydrobrommation led to [2-R-2-( alkoxy-carbonyl)ethyl 1(vinyl)phosphinates III which were isolated and characterized. The Michael addition of diethyl acetamidomalonate to vinylphosphinates III followed by acid hydrolysis of phosphinates VII without their isolation resulted in formation of target [2-R-2-(hydi-oxycai-bonyl)ethyl][')-amino-3-(hydroxycarbonyl)]proyl]phosphinic acids-pseudo-gamma-glutamylpeptides I.

  DOI：

  10.1134/s1070363207050076

文献信息

• [EN] UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY<br/>[FR] INHIBITEURS DE L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) À BASE D'URÉE, POUR IMAGERIE ET TRAITEMENT THÉRAPEUTIQUE
  申请人：FIVE ELEVEN PHARMA INC

  公开号：WO2017116994A1

  公开（公告）日：2017-07-06

  The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

  本发明涉及符合式I和符合式IV的化合物。这些化合物显示出非常好的结合亲和力，能与PSMA结合位点结合。它们可以用[68Ga]GaCl3标记，产率高，放射化学纯度优秀。本发明还涉及包含药用可接受载体和符合式I或符合式IV的化合物，或其药用可接受盐的药物组合物。
• [EN] PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS<br/>[FR] INHIBITEURS DE L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) EN TANT QU'AGENTS DIAGNOSTIQUES ET AGENTS THÉRAPEUTIQUES DE TYPE RADIONUCLÉIDES
  申请人：FIVE ELEVEN PHARMA INC

  公开号：WO2020220023A1

  公开（公告）日：2020-10-29

  The present disclosure relates to compounds according to Formula I. These compounds display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radioactive metal such as [68Ga]or [177Lu]. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or a complex thereof, or a pharmaceutically acceptable salt thereof.

  本公开涉及符合式I的化合物。这些化合物显示出对PSMA结合位点非常好的结合亲和力。它们包括一个放射性同位素或一个能够用放射性金属标记的螯合基团，如[68Ga]或[177Lu]。本公开还涉及包括药用可接受载体和符合式I的化合物或其复合物，或其药用可接受盐的制药组合物。
• DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME
  申请人：BIND Therapeutics, Inc.

  公开号：US20160354320A1

  公开（公告）日：2016-12-08

  The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

  本公开涉及大约0.2至大约35重量百分比的含有治疗剂的纳米颗粒；以及大约10至大约99重量百分比的生物相容性聚合物，例如双嵌段聚（乳酸）-聚（乙烯）乙二醇。该发明的其他方面包括制备这种纳米颗粒的方法。
• Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same
  申请人：Pfizer Inc.

  公开号：US20170266187A1

  公开（公告）日：2017-09-21

  The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

  本公开涉及大约0.2至35重量％喷替芬的纳米颗粒；以及大约10至99重量％的生物相容性聚合物，例如双嵌段聚（乳酸）酸-聚（乙二醇）的聚合物。本发明的其他方面包括制备这种纳米颗粒的方法。
• 18FDG MULTIMERIC POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS
  申请人：Bhushan Kumar Ranjan

  公开号：US20140024803A1

  公开（公告）日：2014-01-23

  The present invention discloses 18 FDG conjugated positron emission tomography (PET) imaging agents. In particular, the present invention discloses a cancer specific 18 FDG multimeric PET imaging agents.

  本发明公开了18FDG结合的正电子发射断层扫描（PET）成像剂。特别地，本发明公开了一种特异性用于癌症的18FDG多聚体PET成像剂。